Low-dose vasopressin in the treatment of vasodilatory septic shock

Journal of Trauma - Injury, Infection and Critical Care

Volumn 47, Issue 4, 1999, Pages 699-705

  Malay, Mary Beth ^a   Ashton, Robert C ^a   Landry, Donald W ^b   Townsend, Ricard N ^a  

^a ALLEGHENY GENERAL HOSPITAL   (United States)

^b Teachers College   (United States)

Author keywords

Hypotension; Low Dose vasopressin; Sepsis

Indexed keywords

DOPAMINE; NORADRENALIN; PHENYLEPHRINE; VASOPRESSIN;

ADULT; ARTICLE; CARDIOVASCULAR EFFECT; CLINICAL ARTICLE; CLINICAL TRIAL; CONTINUOUS INFUSION; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG EFFICACY; FEMALE; HUMAN; HYPOTENSION; INTRAVENOUS DRUG ADMINISTRATION; MALE; MEAN ARTERIAL PRESSURE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SEPTIC SHOCK;

EID: 0032851311     PISSN: 00225282     EISSN: None     Source Type: Journal    
DOI: 10.1097/00005373-199910000-00014     Document Type: Article

References (31)

1. Parillo JE. Septic shock in humans: advances in the understanding of pathogenesis, cardiovascular dysfunction and therapy. Ann Intern Med. 1990;113:227-242.
2. Desjars P, Pinaud M, Potel G, Tasseau F, Touze MD. A reappraisal of norepinephrine therapy in human septic shock. Crit Care Med. 1987;2:134-137.
3. Meadows D, Edwards JD, Wilkins RG, Nightingale P. Reversal of intractable septic shock with norepinephrine therapy. Crit Care Med. 1988;16:663-666.
4. Meadows D, Chernow B, Roth BL. Pharmacologic manipulation of the peripheral vasculature in septic shock: clinical and experimental approaches. Circ Shock. 1986; 18:141-155.
5. Tsuneyoshi I, Kanmura Y, Yoshimura N. Nitric oxide as a mediator of reduced arterial responsiveness in septic patients. Crit Care Med. 1196;24:1083-1086.
6. Houston ML, Thompson WL, Robertson D. Shock: diagnosis and management. Arch Intern Med. 1984; 144:1433-1439.
7. Chernow B, Rainey TG, Lake CR. Endogenous and exogenous catecholamines in critical care medicine. Crit Care Med. 1982;10:409-416.
8. Fink MP, Homer LD, Fletcher JR. Diminished pressor response to exogenous norepinephrine and angiotensin II in septic unanesthetized rats: evidence for a prostaglandin-mediated effect. J Surg Res. 1985;38:335-342.
9. Taguchi H, Heistad DD, Chu Y, Rios CD, Oobushi H, Farachi F. Vascular expression of inducible nitric oxide synthase is associated with activation of Ca++ dependent K+ channels. J Pharmacol Exp Ther. 1996;279:1514-1519.
10. Parillo JE. Pathogenetic mechanisms of septic shock. N Engl J Med. 1993;328:1471-1477.
11. Landry DW, Levin HR, Gallant EM, et al. Vasopressin pressor hypersensitivity in vasodilatory septic shock. Crit Care Med. 1997;25:1279-1282.
12. Landry DW, Levin HR, Gallant EM, et al. Vasopressin deficiency contributes to the vasodilation of septic shock. Circulation. 1997;95:1122-1125.
13. American College of Chest Physicians/Society of Critical Care Medicine Consensus Conference. Definitions for sepsis and organ failure and guidelines for the use of innovative therapies in sepsis. Crit Care Med. 1992;20:864-873.
14. Marshall JC. Multiorgan failure. In: Wilmore DW, Brennan MF, Harken AH, Holcroft JW, Meakins JL, eds. Scientific American Medicine. New York, NY: Scientific American Inc; 1993:13-21.
15. Knaus WA, Draper EA, Wagner DP, Zimmerman JE. APACHE II: a severity of disease classification system. Crit Care Med. 1985;13:818-829.
16. Jackson EK. Vasopressin and other agents affecting the renal conservation of water. In: Gilman AG, Hardman JG, Limbird LE, eds. Goodman and Gilman's The Pharmacological Basis of Therapeutics. New York, NY: McGraw Hill; 1996:715-731.
17. Wagner HW Jr, Braunwald E. The pressor effect of the antidiuretic principle of the posterior pituitary in orthostatic hypotension. J Clin Invest. 1956;35:1412-1418.
18. Reid IA, Schwartz J. Role of vasopressin in the control of blood pressure. In: Martini L, Ganong WF, eds. Frontiers in Neuroendocrinology. New York, NY: Raven Press; 1984:177-197.
19. Ohnishi K, Sato S. Effects of vasopressin on left gastric venous flow in cirrhotic patients with esophageal varices. Am J Gastroenterol. 1990;85:294-295.
20. Morton JJ, Padfield PL. Vasopressin and hypertension in man. J Cardiovasc Pharmacol. 1986;8:S101-S106.
21. Ebert TJ, Crowley AW Jr, Skelton M. Vasopressin reduces cardiac function and augments cardiopulmonary vascular resistance increases in man. J Clin Invest. 1986;77:1136-1142.
22. Mohring J, Glanzer K, Maciel JA, et al. Greatly enhanced pressor response to antidiuretic hormone in patients with impaired cardiovascular reflexes due to idiopathic orthostatic hypotension. J Cardiovasc Pharmacol. 1980;2:367-376.
23. Huch KM, Runyan KR, Wall BM, Gavras H, Cooke R. Hemodynamic response to vasopressin during V1-receptor antagonism in baroreflex-deficient subjects. Am J Physiol. 1995;268:R156-R163.
24. Wolfer RS, Lovell NH, Brunner MJ. Exogenous vasopressin does not enhance carotid baroreflex control in the dog. Am J Physiol. 1994;266:R1510-R1516.
25. Robinson JL. Effect of vasopressin and phenylephrine on arterial pressure and heart rate in conscious dogs. Am J Physiol. 1986;251:H253-H260.
26. Cowley AW Jr, Monos E, Guyton AC. Interaction of vasopressin and the baroreflex system in the regulation of arterial blood pressure in the dog. Circ Res. 1974;34:505-514.
27. Garrad CS, Kontoyannis DA, Piepoli M. Spectral analysis of heart rate variability in the sepsis syndrome. Clin Auton Res. 1993;3:5-13.
28. Bartelstone HJ, Nasomyth PA. Vasopressin potentiation of catecholamines in dog, rat, cat, and rat aortic strip. Am J Physiol. 1965;208:754-762.
29. Benedict CR, Rose JA. Arterial norepinephrine changes in patients with septic shock. Circ Shock. 1992;38:L165-L172.
30. Roth BL, Spitzer JA. Altered hepatic vasopressin and α-1 adrenergic receptors after chronic endotoxin infusion. Am J Physiol. 2987;252:E699-E702.
31. Bendge MJ. Inositol triphosphate and diacylglycerol as second messengers. J Biochem. 1984;220:345-360.